Treatment and trials in non-metastatic castration-resistant prostate cancer
SD Lokeshwar, Z Klaassen, F Saad - Nature Reviews Urology, 2021 - nature.com
Metastatic prostate cancer is associated with considerable morbidity and mortality. Standard
treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen …
treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen …
Chemoprevention of prostate cancer by natural agents: Evidence from molecular and epidemiological studies
Background/Aim: Prostate cancer is one of the most common cancers in men which remains
a global public health issue. Treatment of prostate cancer is becoming increasingly intensive …
a global public health issue. Treatment of prostate cancer is becoming increasingly intensive …
[HTML][HTML] Anti-androgen hormonal therapy for cancer and other diseases
S Student, T Hejmo, A Poterała-Hejmo… - European journal of …, 2020 - Elsevier
The development of targeted therapies has been a consistent goal for hormone-related
diseases treatment. As a result of increased knowledge of the role of androgens in different …
diseases treatment. As a result of increased knowledge of the role of androgens in different …
Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer
Purpose: No published head-to-head randomized trials have compared the safety and
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …
Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer
Z Lin, Z Zhang, X Ye, M Zhu, Z Li, Y Chen, S Huang - Plos one, 2022 - journals.plos.org
Background As a kind of traditional Chinese medicine, HQ is widely mentioned in the
treatment of cancerous diseases in China, which has been proven to have a therapeutic …
treatment of cancerous diseases in China, which has been proven to have a therapeutic …
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?
I Heidegger, MP Brandt, MM Heck - Urologic Oncology: Seminars and …, 2020 - Elsevier
Lately the development of 3 novel second-generation androgen receptor antagonists
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …
A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective
G Ingrosso, M Bottero, C Becherini, S Caini, E Ali… - Seminars in …, 2022 - Elsevier
Prostate cancer is the second most common cause of cancer-related mortality in men. In
patients undergoing a failure after radical treatment, one of the therapeutic option is …
patients undergoing a failure after radical treatment, one of the therapeutic option is …
Cocrystal and Coamorphous Solid Forms of Enzalutamide with Saccharin: Structural Characterization and Dissolution Studies
J Prashanth, KV Drozd, GL Perlovich… - Crystal Growth & …, 2022 - ACS Publications
Cocrystallization and coamorphization are similar yet independent approaches toward
modifying various pharmaceutically relevant properties of modern drug compounds, in …
modifying various pharmaceutically relevant properties of modern drug compounds, in …
Darolutamide: an evidenced-based review of its efficacy and safety in the treatment of prostate cancer
ED Crawford, W Stanton, D Mandair - Cancer Management and …, 2020 - Taylor & Francis
Men treated with androgen deprivation therapy for rising PSA after failed local therapy will
often develop castrate resistance, and the appearance of metastases predicts a poor …
often develop castrate resistance, and the appearance of metastases predicts a poor …
Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation
HJ Cardoso, MI Figueira, CV Vaz, TMA Carvalho… - Cellular Oncology, 2021 - Springer
Purpose Resistance to androgen-deprivation therapies and progression to so-called
castrate-resistant prostate cancer (CRPC) remain challenges in prostate cancer (PCa) …
castrate-resistant prostate cancer (CRPC) remain challenges in prostate cancer (PCa) …